Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma

BACKGROUND: Long-term outcome is unfavourable for relapsed/refractory (r/r) lymphoma patients who are resistant to salvage chemotherapy, even after subsequent autologous stem-cell transplantation (ASCT). Although anti-CD30 chimeric antigen receptor (CAR30) T-cell therapy induces high response rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peiling, Yang, Xiuxiu, Cao, Yang, Wang, Jue, Zhou, Mi, Chen, Liting, Wei, Jia, Mao, Zekai, Wang, Di, Xiao, Yi, Zhu, Haichuan, Zhang, Shangkun, Zhang, Tongcun, Zhang, Yicheng, Zhou, Jianfeng, Huang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578248/
https://www.ncbi.nlm.nih.gov/pubmed/36253833
http://dx.doi.org/10.1186/s40164-022-00323-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578248/
https://www.ncbi.nlm.nih.gov/pubmed/36253833
http://dx.doi.org/10.1186/s40164-022-00323-9

Ejemplares similares